Infectious Diseases

Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments

Basel, June 23, 2022 — Novartis endorses the Kigali Declaration on neglected tropical diseases (NTDs) and announces a five-year financial commitment of USD 250 million to the fight against NTDs and malaria in conjunction with the Kigali Summit on Malaria and NTDs alongside the 26th Commonwealth Heads of Government (CHOGM) meeting. This summit…

MalariaInfectious DiseasesFuture of HealthcareAfricaAccess to Healthcare
Access to Healthcare

Renewing our commitment to neglected tropical disease and malaria elimination

Thierry Diagana and Jonathan Spector from the Novartis Institute for Tropical Diseases (NITD) discuss learnings about their work in Neglected Tropical Diseases (NTDs) and share insights into the factors, which could lead to a resurgence of these diseases.

Access to HealthcareClinical ResearchDrug DevelopmentInfectious DiseasesTropical Diseases
Access to Healthcare

Staying one step ahead of the malaria parasite

Thierry Diagana and his team are on a quest to discover new therapeutics for malaria. He believes malaria elimination is within our grasp, but emerging drug resistance could jeopardize the hard-fought progress.

Access to HealthcareInfectious DiseasesMalariaMedical InnovationsTropical Diseases
Access to Healthcare

Tackling the health toll of climate change

Chronic IllnessEnvironmental SustainabilityInfectious DiseasesMalariaNovartis Institutes for BioMedical Research
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19

Basel, October 28, 2020 — Novartis and Molecular Partners AG today announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423. The collaboration aims to leverage Molecular Partners’…

Reimagine MedicineInfectious DiseasesGlobal Health PartnershipsBiomedical Research
Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19

Basel, December 14, 2020 — Novartis today announced that the Phase III RUXCOVID study evaluating ruxolitinib on top of standard of care (SoC) therapy compared to SoC treatment alone in patients with COVID-19 did not meet its primary endpoint1. Initial data show there was no statistically significant reduction in the proportion of patients on…

Infectious DiseasesEthical Business
Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate

Basel, March 4, 2021 — Novartis announced today that it has signed an initial agreement to manufacture the mRNA and bulk drug product for the COVID-19 vaccine candidate CVnCoV from CureVac to aid in the fight against the COVID-19 pandemic. Preparations for the start of production, technology transfer and test runs are already underway. Following…

Reimagine MedicineInfectious Diseases
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program

Basel, April 2, 2020 — Novartis today announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi® (ruxolitinib) for treatment of a type of severe immune overreaction called cytokine storm that can lead to life-threatening respiratory complications in patients with COVID-191-3.

Social CommitmentInfectious DiseasesGlobal Health Partnerships
Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients

Basel, April 20, 2020 — Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease. The clinical trial drug supply will be provided by Sandoz,…

Social CommitmentScientific ResearchInfectious Diseases
Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe

Holzkirchen, July 27, 2020 – Sandoz, the Novartis generics and biosimilars division, is pleased to announce plans for a joint investment, together with the Austrian federal government, to strengthen the long-term future of integrated antibiotics manufacturing in Europe.

Social CommitmentInfectious DiseasesAccess to Healthcare
Access to Healthcare

Malaria fighter rides bicycle into battle with disease

Healthcare worker Dismus Mwalukwanda is on the front line of the battle against malaria. Saving lives is his priority.

Access to HealthcareDisease EradicationInfectious DiseasesMalariaNovartis Social BusinessTropical Diseases
Access to Healthcare

Streamlining systems to respond to COVID-19

Paul Aliu and his team quickly address requests for Novartis medicines during the pandemic.

COVID-19Infectious DiseasesInnovationWorking at Novartis